| scholarly article | Q13442814 |
| P356 | DOI | 10.1191/0961203303LU340OA |
| P698 | PubMed publication ID | 12729052 |
| P50 | author | Moises Labrador-Horrillo | Q55948479 |
| P2093 | author name string | J L Tovar | |
| A Segarra | |||
| E Balada | |||
| J Ordi-Ros | |||
| M Vilardell-Tarres | |||
| J Cortés-Hernández | |||
| P2860 | cites work | The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 |
| Predictors of renal outcome in diffuse proliferative lupus nephropathy: data from repeat renal biopsy | Q30614385 | ||
| Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease | Q33489732 | ||
| The time-dependence of long-term prediction in lupus nephritis | Q33492379 | ||
| NIH conference. Lupus nephritis | Q34190674 | ||
| Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis | Q34244145 | ||
| Prognostic factors in lupus nephritis. Contribution of renal histologic data | Q36600287 | ||
| Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal | Q40664132 | ||
| Treatment of lupus nephritis: a meta-analysis of clinical trials | Q40906582 | ||
| Factors associated with chronic renal failure in 121 patients with diffuse proliferative lupus nephritis: a case-control study | Q44112212 | ||
| Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. | Q44441787 | ||
| Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus | Q44839857 | ||
| Subnucleosome structures as substrates in enzyme-linked immunosorbent assays | Q46566823 | ||
| "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. | Q50988300 | ||
| Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. | Q54267030 | ||
| Evidence for the Superiority of Immunosuppressive Drugs and Prednisone over Prednisone Alone in Lupus Nephritis | Q57244973 | ||
| P433 | issue | 4 | |
| P921 | main subject | lupus nephritis | Q1621830 |
| P304 | page(s) | 287-296 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone | |
| P478 | volume | 12 |
| Q37866122 | Acquisition of expanded indications for intravenous cyclophosphamide in the management of childhood rheumatic disease in general |
| Q39448909 | Anti-chromatin and anti-histone antibodies in Egyptian patients with systemic lupus erythematosus |
| Q36054578 | Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis |
| Q38086135 | B-cell targeted therapies in systemic lupus erythematosus: successes and challenges. |
| Q37167062 | Biomarkers and updates on pediatrics lupus nephritis |
| Q35968394 | Challenges in bringing the bench to bedside in drug development for SLE. |
| Q38819070 | Comparison of clinical, serological, and prognostic differences among juvenile-, adult-, and late-onset lupus nephritis in Korean patients |
| Q24200954 | Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus |
| Q24246092 | Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus |
| Q37804548 | Drug Monitoring in Systemic Lupus Erythematosus: A Systematic Review |
| Q46484861 | Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study. |
| Q36066014 | Emergence of targeted immune therapies for systemic lupus |
| Q43924407 | Ethnic, clinical and immunological factors in systemic lupus erythematosus and the development of lupus nephritis: results from a multi-ethnic New Zealand cohort |
| Q35907785 | Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis |
| Q39067699 | Infection-related hospitalization and risk of end-stage renal disease in patients with systemic lupus erythematosus: a nationwide population-based study |
| Q44351064 | Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis |
| Q43031095 | Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. |
| Q38073122 | Long-term renal outcome and complications in South Africans with proliferative lupus nephritis |
| Q38453113 | Predictors of renal relapse in Korean patients with lupus nephritis who achieved remission six months following induction therapy |
| Q35626485 | Random spot urine protein/creatinine ratio: a reliable method for monitoring lupus nephritis? |
| Q37186311 | Renal interstitial cells, proteinuria and progression of lupus nephritis: new frontiers for old factors |
| Q39204673 | Renal outcomes among Egyptian lupus nephritis patients: a retrospective analysis of 135 cases from a single centre. |
| Q81205678 | Renal tubular dysfunction in children with systemic lupus erythematosus |
| Q47343114 | Retrospective analysis of nephritis response and renal outcome in a cohort of 928 Egyptian lupus nephritis patients: a university hospital experience |
| Q38153509 | Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis |
| Q38021183 | Role of TWEAK in lupus nephritis: a bench-to-bedside review |
| Q41212927 | The Impact of Baseline Serum Creatinine on Complete Remission Rate and Long-Term Outcome in Patients with Severe Lupus Nephritis |
| Q36666936 | Value of a complete or partial remission in severe lupus nephritis |
| Q54449309 | [Influence of non-complicated urinary tract infection on renal relapses in proliferative lupus nephritis]. |
Search more.